Why Is LIQUIDIA CORP (LQDA) Stock Down Today?

LQDA stock fell by 53.94% to $32.56 in a dramatic intraday session driven by a court ruling in favor of United Therapeutics regarding patent infringement claims. The ruling found Liquidia infringing on two of six claims from United Therapeutics’ ‘327 patent, triggering a sharp sell-off. The stock opened at $71.00 but quickly declined as the legal outcome became public, reaching a session low of $31.50 before resuming trading at 1:40 pm ET.

What Happened

The court decision, issued late in the trading session, concluded that two of the six patent claims asserted by United Therapeutics against Liquidia were valid and infringed. This ruling was a direct blow to Liquidia’s legal position and raised concerns about potential remedies or injunctions. The stock was halted briefly before resuming at a significantly lower price. Truist analysts noted a positive read-through for MannKind’s Tyvaso DPI from the ruling, but the immediate impact on Liquidia was severe. Liquidia’s shares continued to fall throughout the afternoon session, with the last trade at $32.68. The ruling also mandated that both parties submit a proposed form of judgment within one week for the court’s consideration.

What The Data Shows

The intraday session saw 13.6 million shares traded, which is 8.0 times the 3-month daily average, indicating a surge in selling pressure. The stock had previously printed nine fresh 52-week lows on September 30. Over the last 8 sessions, LQDA had risen 7.7%, but the recent legal setback reversed that trend. Insiders sold a total of $56.9 million in the last 90 days, with the most recent filing on September 15. Liquidia’s fundamentals remain strong, with a TTM revenue increase of 2233.6% and a net margin of 30.7%, but the legal uncertainty overshadowed these metrics.

What To Watch

Investors should monitor the proposed remedy submissions due within one week and watch for any updates on the final judgment. The stock’s volatility and legal exposure remain key focal points.